Nantahala Capital Management LLC Trims Stake in Rallybio Corporation $RLYB

Key Points

• Nantahala Capital Management cut its Rallybio stake by 37.3% in the second quarter, selling 112,213 shares and retaining 188,422 shares worth about $3.0 million. Institutional investors collectively own 90.34% of the company.
• Other major investors increased their positions, notably ADAR1 Capital Management, which expanded its holdings by 4,411.1%, and BlackRock, which raised its stake by 73.5%. Analyst sentiment remains cautious, with Rallybio holding a consensus “Hold” rating.
• Rallybio shares opened at $16.81, near their 52-week high of $17.57, while the company reported a quarterly loss of $1.09 per share—better than the expected $1.28 loss. Despite the earnings beat, the company continues to post deeply negative margins and return on equity.

Nantahala Capital Management LLC lessened its holdings in Rallybio Corporation (NASDAQ:RLYB - Free Report) by 37.3% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 188,422 shares of the company's stock after selling 112,213 shares during the period. Nantahala Capital Management LLC owned 3.55% of Rallybio worth $3,014,752 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in RLYB. ADAR1 Capital Management LLC grew its position in shares of Rallybio by 4,411.1% in the 2nd quarter. ADAR1 Capital Management LLC now owns 926,352 shares of the company's stock valued at $14,822,000 after acquiring an additional 905,817 shares during the period. BlackRock Inc. raised its holdings in shares of Rallybio by 73.5% in the 2nd quarter. BlackRock Inc. now owns 30,332 shares of the company's stock valued at $485,000 after purchasing an additional 12,846 shares during the period. XTX Topco Ltd raised its holdings in shares of Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after purchasing an additional 38,205 shares during the period. Renaissance Technologies LLC lifted its stake in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after purchasing an additional 120,892 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock valued at $170,000 after purchasing an additional 2,996 shares during the last quarter. Institutional investors own 90.34% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Wall Street Zen raised Rallybio from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Weiss Ratings raised Rallybio from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of "Hold".

Rallybio Stock Performance

Shares of Rallybio stock opened at $16.81 on Friday. The firm has a 50-day moving average of $16.27 and a 200-day moving average of $12.63. Rallybio Corporation has a 52-week low of $3.67 and a 52-week high of $17.57. The stock has a market cap of $89.26 million, a PE ratio of -3.87 and a beta of -0.90.

Rallybio (NASDAQ:RLYB - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.28) by $0.19. Rallybio had a negative return on equity of 40.53% and a negative net margin of 911.07%.

Rallybio Company Profile

Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.